Cancer drug niraparib gets Long-Term safety check in extension trial

NCT ID NCT04641247

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued access to niraparib, a daily oral cancer drug, for up to 37 patients with ovarian or breast cancer who have already completed a prior niraparib trial and are still benefiting. The main goal is to monitor long-term safety, including side effects and changes in daily functioning. Participants will continue their current niraparib dose and be followed for any health issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Niraparib (a targeted cancer drug taken as a daily pill)
What this could lead to: If successful, this study could confirm that long-term niraparib is safe and continues to control ovarian or breast cancer, offering a maintenance treatment option.
What could go wrong: This is a small, open-label extension study (37 participants) focused on safety, not on proving the drug works better. It only includes people who already tolerated niraparib, so results may not apply to all patients. Side effects like fatigue, nausea, or blood issues remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm ovarian cancer ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS OVARIAN NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site
COMPLETED

Tucson, Arizona, 85710, United States
GSK Investigational Site
RECRUITING

Encinitas, California, 92024, United States
GSK Investigational Site
RECRUITING

Los Angeles, California, 90048, United States
GSK Investigational Site
COMPLETED

Whittier, California, 90603, United States
GSK Investigational Site
COMPLETED

Jacksonville, Florida, 32224, United States
GSK Investigational Site
RECRUITING

Atlanta, Georgia, 30342, United States
GSK Investigational Site
RECRUITING

Harvey, Illinois, 60426, United States
GSK Investigational Site
RECRUITING

Boston, Massachusetts, 02115, United States
GSK Investigational Site
RECRUITING

Grand Rapids, Michigan, 60637-1470, United States
GSK Investigational Site
RECRUITING

Morristown, New Jersey, 07962-1956, United States
GSK Investigational Site
RECRUITING

Lake Success, New York, 11042, United States
GSK Investigational Site
RECRUITING

Charlotte, North Carolina, 28204, United States
GSK Investigational Site
COMPLETED

Cleveland, Ohio, 44195, United States
GSK Investigational Site
RECRUITING

Graz, A-8036, Austria
GSK Investigational Site
RECRUITING

Vienna, 1090, Austria
GSK Investigational Site
RECRUITING

Kelowna, British Columbia, V5Z 4E6, Canada
GSK Investigational Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site
COMPLETED

Odense C, 5000, Denmark
GSK Investigational Site
COMPLETED

Nantes, 44202, France
GSK Investigational Site
COMPLETED

Nice, 06189, France
GSK Investigational Site
RECRUITING

Haifa, 3109601, Israel
GSK Investigational Site
RECRUITING

Cremona, 26100, Italy
GSK Investigational Site
RECRUITING

Madrid, 28040, Spain
GSK Investigational Site
RECRUITING

Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.